EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea

Seok Woo Moon, Jee Wook Kim, Do Hoon Kim, Kyu Young Lee, Elin Heldbo Reines, Minah Lee, Yoo Jin Park

Frontiers in Psychiatry · 02.03.2023 · 14

DOI: 10.3389/fpsyt.2023.1075939 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychiatry, online erschienen am 02.03.2023. Verfasst von Seok Woo Moon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropsychiatry, Konkuk University School of Medicine, Chungju-si, Republic of Korea. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A post-marketing surveillance study was conducted to assess the real-world safety and effectiveness of vortioxetine for the treatment of major depressive disorder (MDD) in South Korea.

Methods

Adult patients aged 19–94 years receiving vortioxetine for MDD at 72 hospitals and clinics in South Korea between 19 th August 2014 and 18 th August 2020 were included. Patients were followed for up to 24±2 weeks, at up to three visits. Adverse events (AEs) and effectiveness, assessed by both clinician and patient-reported measures, were analyzed.

Results

A total of 3,263 patients (mean age: 51.28 years) were included in the safety set; 1,095 were aged ≥65 years. The majority of the safety set (61.97%) were female. The overall rate of any AEs and serious AEs were 17.13 and 1.56%, respectively. The majority of AEs were mild (88.32%). The rates of AEs did not differ statistically by age (≥65 years: 16.89% [185/1,095] versus <65 years: 17.25% [374/2,168)], p =0.7989), sex (male: 15.95% [198/1,241] versus female: 17.85% [361/2,022], p =0.1623), or liver impairment (with liver impairment: 20.90% [14/67] versus without liver impairment: 17.05% [545/3,196], p =0.4087). Effectiveness was assessed in 1,918 patients. By 24±2 weeks, there were significant clinical improvements from baseline, assessed by change in Montgomery-Asberg Depression Rating Scale total score (mean±standard deviation [SD]: -10.49±9.42 points, p <0.0001), the proportion of patients with improved symptoms using the Clinical Global Impression - Improvement scores (79.29%), and in both patient-reported measures, with a significant improvement in the Korean Version of the Perceived Deficits Questionnaire-Depression (mean±SD: -6.06±13.23, p <0.0001) and Digit Symbol Substitution Test (mean±SD: 4.83±9.81, p <0.0001) total scores from baseline. Similar to the safety profiles, the proportions of patients with improved symptoms compared with baseline using the Clinical Global Impression – Improvement scores did not differ by age (≥65 years: 82.09% versus <65 years: 78.32%, p =0.0511), sex (male: 77.45% versus female: 81.01%, p =0.0587), or liver impairment (with liver impairment: 67.57% versus without liver impairment: 79.85%, p =0.0663).

Conclusion

Vortioxetine appears to be well-tolerated and effective for treating MDD patients in the real-world setting in South Korea, irrespective of age, sex, and liver impairment, reflecting the known profile of vortioxetine based on studies worldwide.

Schlagwörter

Stichwörter der Autor:innen

South Koreaantidepressantsmajor depressive disordernon-interventionalpost-marketing surveillancevortioxetine

Autor:innen und Institutionen

  • Department of Neuropsychiatry, Konkuk University School of Medicine, Chungju-si, Republic of Korea.
  • Department of Neuropsychiatry, Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Republic of Korea.
  • Department of Psychiatry, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon-si, Republic of Korea.
  • Mind-Neuromodulation Laboratory, College of Medicine, Hallym University, Chuncheon-si, Republic of Korea.
  • Department of Psychiatry, Nowon Eulji Medical Center, Seoul, Republic of Korea.
  • Department of MSC Vortioxetine and Established Products, H. Lundbeck A/S, Copenhagen, Denmark.

Zitieren

APA

Moon, S. W., Kim, J. W., Kim, D. H., Lee, K. Y., Reines, E. H., Lee, M., & Park, Y. J. (2023). Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1075939

Vancouver

Moon SW, Kim JW, Kim DH, Lee KY, Reines EH, Lee M, et al. Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea. Frontiers in Psychiatry. 2023;14. doi:10.3389/fpsyt.2023.1075939

BibTeX
@article{Moon2023,
  author = {Moon, Seok Woo and Kim, Jee Wook and Kim, Do Hoon and Lee, Kyu Young and Reines, Elin Heldbo and Lee, Minah and Park, Yoo Jin},
  title = {Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea},
  journal = {Frontiers in Psychiatry},
  year = {2023},
  volume = {14},
  doi = {10.3389/fpsyt.2023.1075939}
}
Kostenlos starten →